Fibrinogen (Factor I) is a soluble plasma glycoprotein that is essential for blood clotting. Traditionally derived from human plasma, the biopharmaceutical industry is undergoing a paradigm shift towards Recombinant Fibrinogen. This transition is driven by the need for viral safety, batch-to-batch consistency, and a scalable supply chain that is not dependent on blood donations.
"Recombinant technology allows for the expression of the Aα, Bβ, and γ chains of fibrinogen in controlled bioreactor environments, ensuring a product free from human-derived pathogens like HIV or Hepatitis."
Our High-Quality Recombinant Fibrinogen products are engineered to mimic the structural and functional properties of natural human fibrinogen, providing a high-purity alternative for surgical sealants, wound healing, and 3D bioprinting applications.
Year Established
Global Clients
Product Purity
Annual Sales
Utilizing Pichia pastoris and CHO cell lines for optimized protein folding and post-translational modifications, ensuring biological activity equivalent to plasma-derived variants.
Multi-step chromatography processes (affinity and ion exchange) achieve ultra-low endotoxin levels, meeting the stringent requirements of clinical-grade applications.
The future of Recombinant Fibrinogen lies in "Bio-Ink." We are developing customized formulations for tissue engineering and artificial organ scaffolds.
Jiangxi Serum Pharma Industries Co., Ltd. leverages the unique strengths of the Chinese manufacturing ecosystem. Our localized supply chain provides a "Triple-A" advantage: Availability, Affordability, and Agility.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, and western medicines.
Established in 2017, we have built a network of 200+ close-related suppliers, ensuring that even in times of global shortage, our Recombinant Fibrinogen supply remains uninterrupted.
Where High-Quality Recombinant Fibrinogen makes a difference.
Used as a critical component in fibrin glues to stop bleeding in cardiovascular and orthopedic surgeries without risk of transfusion-related infections.
Serves as a high-purity standard for coagulation assays and prothrombin time (PT) testing in clinical laboratories.
Incorporated into bioactive dressings for diabetic ulcers and severe burns, promoting cell migration and tissue regeneration.
Exploring the shift toward sustainable sources in the pharmaceutical lipid market.
Why this molecule remains critical in modern emergency medicine.
Eli Lilly's Foundayo™ approval sets a record 50-day process, impacting the peptide drug landscape.
Plasma-derived fibrinogen is extracted from human blood donors, carrying inherent risks of viral contamination. Recombinant fibrinogen is produced in a bioreactor using genetically modified cells, ensuring 100% safety from human pathogens and superior consistency.
Yes. Extensive in-vitro and in-vivo studies show that our recombinant products maintain identical clottability, fiber structure, and interaction with thrombin and Factor XIII as the native human protein.
For long-term stability, it is typically supplied as a lyophilized powder and should be stored at 2°C to 8°C. Once reconstituted, it should be used within a specified timeframe to maintain maximum potency.
Jiangxi Serum Pharma provides comprehensive technical documentation, including COA, stability data, and support for your local regulatory compliance requirements.
